Back to results
US 8,090,562 B2Granted
Predicting risk of major adverse cardiac events
AssigneeCritical Care Diagnostics, Inc.
InventorsJames V. Snider, Eugene R. Heyman
Life of this patent
Estimating the term…
Abstract
Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
Claims18
A method for evaluating a subject's risk of a major adverse cardiac event (MACE) within one year, the method comprising:
- determining a first level of soluble Growth Stimulation-Expressed Gene 2 (ST2) in a biological sample obtained from a subject at a first time point (ST2T0), a second level of soluble ST2 in a biological sample obtained from a subject at a second time point (ST2T1), and a level of natriuretic peptide (NP) in a biological sample obtained from a subject at the second time point (NPT1);
- determining a MACE risk score (MACERS) for a subject utilizing, at least in part, a ratio of ST2T1 to ST2T0, in combination with a weighted logarithm of NPT1, and
- comparing the MACERS to a reference MACERS;
- wherein the MACERS in comparison with the reference MACERS is indicative of the subject's risk of a MACE within one year.
1 more element
Dependencies are inferred from the claim text.